Phase 3 Schizophrenia Trial, Recruiting NCT07045142 Sponsor: Central South University Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT07045142
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old and have been diagnosed with schizophrenia according to standard medical guidelines (DSM-5)
  • Your symptoms and medications have been stable for more than 3 months, and you are taking no more than two antipsychotic medications (other medications such as antidepressants or anxiety medications are also allowed)
  • Short-term use of a type of calming medication called benzodiazepines is permitted
  • Your fasting blood tests show at least one of the following: total cholesterol of 5.2 mmol/L or higher, triglycerides of 1.7 mmol/L or higher, or LDL ("bad") cholesterol of 3.4 mmol/L or higher
  • Two separate fasting blood sugar tests (taken 1–4 weeks apart) both show a result below 6.1 mmol/L
  • You are able to attend all study appointments without major issues related to moving, travel, or accessing healthcare during the study
  • Both you and your legal guardian are willing to give written consent to take part

Who may not be able to join:

  • You have previously been diagnosed with diabetes or have had a serious diabetes-related complication such as diabetic ketoacidosis
  • You have liver or kidney problems, shown by certain blood test results being significantly above the normal range (confirm with trial site)
  • You have a serious condition affecting the gut, lungs, hormones, blood, or your body's ability to absorb nutrients — including poorly controlled diabetes, serious infections, heart disease, a stroke within the past year, a history of abnormal heart rhythm, active hepatitis B or C, or conditions affecting nutrient absorption
  • Your heart tracing (ECG) at the screening stage shows certain abnormalities — for example, a specific heart rhythm measurement (QTc interval) that is too high for your gender (confirm with trial site)
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Renrong Wu, Mental Health Institute of Second Xiangya Hospital,CSU

Phone: +86 15874290980

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Central South University
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from Baseline in Fasting Blood Glucose Concentration; Change from Baseline in Glycated Hemoglobin (HbA1c) Concentration; Oral Glucose Tolerance Test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov